For mood-disorder diagnostics, biomarkers, and therapeutics: we validate whether patients trust, accept, and act on your solution outside the trial bubble.
Your data may be strong, publications solid, and KOL support real. But diagnostic and treatment adoption still fails when real-world behavior does not match trial assumptions. Investors and payers are asking one question: will people use this outside controlled settings?
Most teams validate inside trials. Few validate outpatient adoption behavior before go-to-market.
We provide a Trained Patient Expert Network: method-driven, compensated, and structured for strategic missions. We test whether your science becomes real-world behavior.
We bridge trial evidence and outpatient reality so founders can show a credible adoption story to investors, payers, and partners.
We map how real patients move from uncertainty to treatment decisions in mood disorders.
Scientific validity alone does not create adoption.
What matters is whether people trust, accept, and act on what you diagnose.
That is the missing proof for fundraising and reimbursement conversations.
We generate that proof.
Patients receive a diagnostic signal, but often do not know what it means for their life, identity, or next step.
Clarity and emotional relevance come before action.
Patients compare stories, clinician feedback, and community opinions before they trust novel diagnostics or therapies.
This is where adoption is built or lost.
The final step is behavior: follow-up, treatment initiation, adherence, and ongoing engagement.
Adoption is proven only when diagnosis changes behavior in real life.
We turn lived experience into structured evidence that helps biotech teams:
Clear proof that your solution can drive real-world adoption, not just trial results.
Built for CEO, Founder, and CSO teams preparing go-to-market, reimbursement, and the next raise.
Phase 1
Patient interviews, focus groups, journey mapping, and trial-vs-reality gap analysis to produce a clear adoption risk report.
Phase 2
Persona refinement, behavioral segmentation, go-to-market psychology, and positioning for adoption, access, and investor conversations.
Phase 3
Patient-led content, testimonial capture, campaign strategy, and ambassador programs that convert insight into measurable traction.
Outcome
Use adoption intelligence to de-risk reimbursement, strengthen partner confidence, and support your next fundraising round.
A focused model for mood-disorder biotech to validate real-world behavior before scale.
Run a fast adoption diagnostic to identify where trial assumptions break in outpatient reality.
Outcome: Adoption Risk Report
Timeline: 2-4 weeks | Typical scope: 10k-25k
Translate findings into an adoption strategy founders can execute and defend in investor conversations.
Outcome: Strategic Adoption Roadmap
Timeline: 4-6 weeks | Typical scope: 25k-60k
Deploy adoption assets and keep validating behavior as you scale trials, access, and launch readiness.
Outcome: Ongoing Adoption Proof Points
Timeline: Optional recurring support
De-risked adoption story for your next round
Clear adoption evidence that strengthens strategic decisions and investor confidence.
More credible payer and partner narrative for real-world demand and uptake.
Not a CRO.
We do not run your trial operations; we validate whether outcomes will translate into behavior outside trials.
Not generic marketing.
We deliver structured lived-experience intelligence that informs product, positioning, and adoption decisions.
Mood-disorder adoption bridge.
We connect science to real patient action for biomarker, therapeutic, and precision psychiatry companies.
We conducted a full patient-led research program for Alcediag: qualitative interviews with patients and relatives, a quantitative survey, focus groups, and persona creation. Insights were then used to build their go-to-market strategy, value proposition, and segment-specific funnels for their bipolarity/depression blood test.
We created patient-led content grounded in real language, behaviour, and emotional patterns from our communities. This included blog articles, podcast segments, and social content aimed at building trust, improving engagement, and supporting early adoption.